A phase I/II clinical trial exploring safety and efficacy of anti-CD7 allogeneic CAR-T (WU-CART-007) in patients with relapsed or refractory T-ALL and T-LBL for patients aged 12 years and older is currently enrolling (NCT04984356). This evidence concerns the gene CD7 and acute lymphoblastic leukemia.